3. PARPi monotherapy had no negative effect on subsequent platinum-based chemotherapy and could improve prognosis.
27 patients with a median PFI of 20.2 months were treated with subsequent platinum-based chemotherapy after PARPi progression, and were enrolled in study group 2 ; Among the 23 patients in the control group without PARPi history, PFI of 22 patients after third-line platinum-based chemotherapy was obtained, including 14 platinum-sensitive relapsed patients (PFI≥6 months), 13 of whom underwent subsequent platinum-based chemotherapy (Control group 2), and 8 platinum-resistant relapsed patients (PFI<6 months, Control group 3). The baseline characteristics of the patients were shown in Table 2 and Table S3. We compared the TFST of patients with platinum-based chemotherapy after the progression of PARPi and with patients in control group 2, and the result showed no statistical difference (Figure 2C; mTFST: 7.5 vs. 7.1 months, HR=1.11, p=0.800). Further survival analysis showed that PRS of patients in study group 2 was similar to platinum-sensitive relapse patients after third-line platinum chemotherapy (Figure 2D; mPRS: NR vs. 42.2 months, HR=0.66, p=0.503), and superior to platinum-resistant relapse patients after third-line platinum chemotherapy (Figure 2D; mPRS: NR vs. 23.7 months, HR=0.15, p=0.009).